MannKind develops dry powder inhaler for pulmonary hypertension treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/8/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- Atlassian results seen as 'game changer' for AI kills software worries
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
May 6, 2026 6:30 AM EDTThe formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPIUnited Therapeutics plans to be the primary manufacturer of ralinepag DPIMannKind eligible to receive up to $35 million in development milestones plus 10% royalties on net sales
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:... More
